Jefferies downgraded Vigil Neuroscience (VIGL) to Hold from Buy with a price target of $8, down from $19, after Sanofi (SNY) agreed to acquire the company for $8 per share in cash plus a non-tradeable contingent value right entitling the holder to potentially receive an additional $2.00 per share in cash.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIGL:
- Vigil Neuroscience downgraded to Neutral from Outperform at Wedbush
- Vigil Neuroscience Enters Merger Agreement with Sanofi
- Vigil Neuroscience downgraded to Neutral from Buy at Guggenheim
- Vigil Neuroscience downgraded to Market Perform from Outperform at William Blair
- Vigil Neuroscience downgraded to Market Perform from Outperform at Citizens JMP